MichaelGlenKauffmanMDPhD

PubMed

• 23 citations
  Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib.
  Wenwen Chien, Makoto Sudo, Ling-Wen Ding, Qiao-Yang Sun, Peer Wuensche, Kian Leong Lee, Norimichi Hattori, Manoj Garg, Liang Xu, Yun Zheng, Sigal Gery, Sarawut Wongpha...> ;Journal of Cancer. 2018 Dec 10
• 10 citations
  Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
  Amro Aboukameel, Irfana Muqbil, Erkan Baloglu, William Senapedis, Yosef Landesman, Christian Argueta, Michael Kauffman, Hua Chang, Trinayan Kashyap, Sharon Shacham, Ja...> ;Oncotarget. 2018 Oct 19
• 39 citations
  Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
  Trinayan Kashyap, Christian Argueta, Thaddeus J. Unger, Boris Klebanov, Sophia A. Debler, William Senapedis, Marsha Crochiere, Margaret S. Lee, Michael Kauffman, Sharo...> ;Oncotarget. 2018 Jul 20
• 91 citations
  Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
  C. Chen, David A. Siegel, Martin Gutierrez, Meagan A. Jacoby, Craig C. Hofmeister, Nashat Y. Gabrail, Rachid Baz, Morten Mau-Sørensen, Jesus G. Berdeja, Michael R. Sav...> ;Blood. 2018 Feb 22
• Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
  Gravina, G. L.,Mancini, A.,Colapietro, A.,Marampon, F.,Sferra, R.,Pompili, S.,Biordi, L. A.,Iorio, R.,Flati, V.,Argueta, C.,Landesman, Y.,Kauffman, M.,Shacham, S.,Fest...> ;Oncotarget. 2018 Jan 18
• 6 citations
  XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
  Marsha Crochiere, Stefan Hannus, Kerrin Hansen, Frank Becker, Erkan Baloglu, Margaret S. Lee, Michael Kauffman, Sharon Shacham, Yosef Landesman> ;Oncotarget. 2017 Nov 30
• 30 citations
  Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
  Asfar S. Azmi, Yiwei Li, Irfana Muqbil, Amro Aboukameel, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M...> ;Oncotarget. 2017 Jul 17
• 79 citations
  KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
  Julia Etchin, Alla Berezovskaya, Amy Saur Conway, Ilene Galinsky, Richard Stone, Erkan Baloglu, William Senapedis, Yosef Landesman, M. Kauffman, S. Shacham, Jean C.Y. ...> ;Leukemia. 2017 Jan 1
• 95 citations
  Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
  Zachary A. Hing, Ho Yee Joyce Fung, Parvathi Ranganathan, Shaneice Mitchell, Dalia El-Gamal, Jennifer A. Woyach, Katie Williams, Virginia M. Goettl, Jordan Smith, Xuey...> ;Leukemia. 2016 May 20
• Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cance...
  Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, Landesman Y, McCauley D, Kauffman M, Shacham S, Festuccia C> ;BMC Cancer. 2016-01-11
• 65 citations
  Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
  Julia Etchin, Joan Montero, Alla Berezovskaya, Bonnie Thi Le, Alex Kentsis, Amanda L. Christie, Amy Saur Conway, Weihsu Claire Chen, Casie Reed, Marc R. Mansour, C E L...> ;Leukemia. 2016 Jan 1
• 39 citations
  Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
  Shaun Rosebeck, Mattina Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, Sean P. Maxwell, Stephanie J Kraftson, Di...> ;Molecular Cancer Therapeutics. 2016 Jan 1
• 24 citations
  Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
  Asfar S. Azmi, Irfana Muqbil, Jack Wu, Amro Aboukameel, William Senapedis, Erkan Baloglu, Aliccia Bollig-Fischer, Gregory Dyson, Michael Kauffman, Yosef Landesman, Sha...> ;Scientific Reports. 2015 Nov 5
• 26 citations
  Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
  Yoko Tabe, Kensuke Kojima, Shinichi Yamamoto, Kazumasa Sekihara, Hiromichi Matsushita, Richard E. Davis, Zhiqiang Wang, Wencai Ma, Jo Ishizawa, Saiko Kazuno, Michael K...> ;Plos One. 2015 Sep 4
• 41 citations
  Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
  Parvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, Jessica N Hofstetter, Alison Walker, Katherine Walsh, Bhavana Bhatnagar, Rebecca B. Klisovic, Sumithira Vasu, Mitc...> ;Blood. 2015 Apr 23
• 33 citations
  shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
  Jamshid S. Khorashad, Anna M. Eiring, Clinton C. Mason, Kevin C. Gantz, Amber D. Bowler, Hannah M. Redwine, Fan Yu, Ira L. Kraft, Anthony D. Pomicter, Kimberly R. Reyn...> ;Blood. 2015 Mar 12
• 21 citations
  Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth
  Hiromi I. Wettersten, Yosef Landesman, Sharon Friedlander, Sharon Shacham, Michael Kauffman, Robert H. Weiss> ;Plos One. 2014 Dec 2
• 38 citations
  Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
  Jennifer Yang, Matthew A. Bill, Gregory S. Young, Krista M. D. La Perle, Yosef Landesman, Sharon Shacham, Michael Kauffman, William Senapedis, Trinayan Kashyap, Jean-R...> ;Plos One. 2014 Jul 24
• 53 citations
  KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma
  Yun Zheng, Sigal Gery, Haibo Sun, Sharon Shacham, Michael Kauffman, H. Phillip Koeffler> ;Cancer Chemotherapy and Pharmacology. 2014 Jul 17
• 52 citations
  KPT-330 has antitumour activity against non-small cell lung cancer
  Haibo Sun, Norimichi Hattori, Wenwen Chien, Qiao-Yang Sun, Makoto Sudo, G L E-Ling, Ling-Wen Ding, Su Lin Lim, Sharon Shacham, M. Kauffman, Tsuyoshi Nakamaki, H P Koef...> ;British Journal of Cancer. 2014 Jul 15
• 45 citations
  Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
  Yiming Zhong, Dalia El-Gamal, Jason A. Dubovsky, Kyle A. Beckwith, Bonnie K. Harrington, Katie Williams, Virginia M. Goettl, Shruti Jha, Xiaokui Mo, Jeffrey A. Jones, ...> ;Leukemia. 2014 May 1
• 79 citations
  XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
  Yan Cheng, Michael P. Holloway, Kevin Nguyen, Dilara McCauley, Yosef Landesman, Michael Kauffman, Sharon Shacham, Rachel A. Altura> ;Molecular Cancer Therapeutics. 2014 Mar 1
• 72 citations
  Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
  Cheryl A. London, Luis Feo Bernabe, Sandra Barnard, William C. Kisseberth, Antonella Borgatti, Michael S. Henson, Heather L. Wilson, Kiersten Jensen, Daisuke Ito, Jaim...> ;Plos One. 2014 Feb 4
• 125 citations
  Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
  Jessica Schmidt, Esteban Braggio, Klaus Martin Kortuem, Jan B. Egan, Yuanxiao Zhu, C S Xin, Rodger E. Tiedemann, Stephen Palmer, Victoria M. Garbitt, D. McCauley, M. K...> ;Leukemia. 2013 Jun 11
• 114 citations
  Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
  Christopher J. Walker, Joshua J. Oaks, Ramasamy Santhanam, Paolo Neviani, Jason G. Harb, Gregory Ferenchak, Justin Ellis, Yosef Landesman, Ann-Kathrin Eisfeld, Nash Ga...> ;Blood. 2013 Oct 24
• Join now to see all

Abstracts/Posters

• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018